Page last updated: 2024-10-24

negative regulation of synaptic vesicle clustering

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of synaptic vesicle clustering. [PMID:21513708]

Negative regulation of synaptic vesicle clustering is a complex process that ensures proper synaptic function and plasticity. It involves a fine-tuned interplay of molecular players that regulate the aggregation and distribution of synaptic vesicles (SVs) at presynaptic terminals. Here's a detailed breakdown of the key mechanisms:

**1. Regulation of SNARE Complex Assembly and Disassembly:**
- **SNARE proteins** (Synaptic protein receptors) are critical for SV fusion with the presynaptic membrane. Proteins like **synaptotagmin** and **complexin** are involved in the assembly and disassembly of the SNARE complex, directly impacting SV clustering.
- **Negative regulation** occurs when the SNARE complex is prevented from forming or is disrupted, reducing the efficiency of SV fusion and clustering.

**2. Activity-Dependent Mechanisms:**
- **Calcium signaling:** Upon neuronal activation, calcium influx triggers a cascade of events that regulate SV clustering. Increased calcium can lead to the recruitment of proteins like **endophilin** and **dynamin**, promoting SV endocytosis and reducing clustering.
- **Phosphorylation events:** Phosphorylation of key proteins involved in SV clustering can modulate their activity. For example, phosphorylation of **synapsin I** by **calcium/calmodulin-dependent protein kinase II** (CaMKII) can detach SVs from the cytoskeleton, reducing their clustering.

**3. Cytoskeletal Dynamics:**
- **Actin and microtubule networks** play a crucial role in SV clustering. Proteins like **actin-binding proteins** (e.g., spectrin, drebrin) and **microtubule-associated proteins** (e.g., MAP2, tau) regulate the organization of these cytoskeletal elements.
- **Negative regulation** can involve modifying the organization of these cytoskeletal networks, thereby influencing SV distribution.

**4. Endocytosis and Recycling:**
- After SV fusion, the membrane is retrieved through endocytosis, a process that influences SV clustering. Factors like **clathrin** and **dynamin** are critical for endocytosis, and their dysregulation can impact SV clustering.

**5. Molecular Chaperones and Scaffolding Proteins:**
- **Chaperones** like **HSP70** can facilitate the proper folding and assembly of proteins involved in SV clustering, while **scaffolding proteins** (e.g., **PSD-95**) can anchor and organize these proteins at the synapse.
- Disruption of these chaperones and scaffolding proteins can lead to a reduction in SV clustering.

**6. Regulation of SV Size and Number:**
- **SV size and number** can be influenced by the activity of proteins like **Rab GTPases** and **synaptophysin**, which contribute to the biogenesis and recycling of SVs.
- Reduced SV size or number can indirectly affect clustering.

**7. Neuronal Activity and Plasticity:**
- **Long-term potentiation (LTP)**, a form of synaptic plasticity, can lead to increased SV clustering. Conversely, **long-term depression (LTD)** often involves reduced SV clustering.
- Negative regulation can contribute to the weakening of synapses during LTD.

**In summary:**
The negative regulation of synaptic vesicle clustering is an intricate process that involves the coordinated interplay of numerous molecular players. It is essential for maintaining proper synaptic function, enabling precise control over neurotransmitter release, and supporting the dynamic changes in synaptic strength that underpin learning and memory.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTENA phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN that is encoded in the genome of human. [PRO:PD, UniProtKB:P60484]Homo sapiens (human)

Compounds (1)

CompoundDefinitionClassesRoles
celastrolmonocarboxylic acid;
pentacyclic triterpenoid
anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite